News that Samsung Biologics is facing a probe by South Korean regulators over its valuation ahead of an initial public offering last year sent its share price down this week in Seoul. South Korea’s Financial Supervisory Service is running a special audit of the drugs contract manufacturer, prompted by a Korean Institute of Certified Public Accountants review that found “unclear […]
Samsung BioLogics
Samsung Biologics IPO could reach $2B, company value above $8B
Biotech drug contract manufacturer Samsung BioLogics could pull in as much as $2 billion through an initial public offering, according to regulatory filings posted this week. The figures would position it as South Korea’s 3rd-largest IPO. BioLogics, which is 47.8% owned by Samsung Electronics (LON:BC94), this week gave new information on the planned offering, which would value the […]
